Using CGM to Reverse Prediabetes: Research and Protocol

Can a Small Sensor on Your Arm Help Reverse Prediabetes?

For the estimated 98 million Americans living with prediabetes, the stakes couldn't be higher. Without intervention, up to 70% will progress to type 2 diabetes within their lifetime. But a growing body of research suggests that continuous glucose monitors (CGMs) — tiny sensors originally developed for people already living with diabetes — may be one of the most powerful tools available to stop that progression, or even reverse it entirely.

The core idea is simple but powerful: you can't change what you can't see. Traditional prediabetes management relies on HbA1c tests taken every few months, which provide only a rough average of blood sugar over time. CGMs give users a continuous, real-time picture of how their blood sugar rises and falls in response to specific foods, stress, sleep, and exercise — information that was simply unavailable to most patients just a decade ago.

What the Research Shows

Several meaningful studies have now examined CGM use specifically in people with prediabetes or those at high risk for type 2 diabetes, and the results are encouraging.

A landmark study published in Nature Medicine (2020) by researchers at Stanford, analyzing data from over 1,000 participants, demonstrated that blood sugar responses to identical foods vary dramatically between individuals — a phenomenon researchers call "glycemic variability." This finding suggests that blanket dietary advice ("avoid sugar," "eat less carbs") is far less effective than personalized guidance based on an individual's actual glucose data. CGMs make that personalized guidance possible.

The SHIFT Study (Self-monitoring with Health Intervention for Type 2 prevention), conducted in the UK with participants with prediabetes, found that CGM use combined with structured dietary coaching led to significantly greater reductions in postprandial glucose spikes compared to standard dietary advice alone. Participants using CGMs were better able to identify their personal "trigger foods" and make sustainable behavioral changes.

More recently, Levels Health and January AI have published internal and peer-reviewed research suggesting that structured CGM-guided programs in prediabetes populations can produce meaningful reductions in HbA1c over 12-week periods. While company-sponsored research warrants careful interpretation, these results align with independent academic findings.

A 2023 randomized controlled trial published in JAMA Internal Medicine examined CGM use in adults with prediabetes over 26 weeks. Participants using CGMs alongside a structured behavioral intervention showed statistically significant reductions in fasting glucose and HbA1c compared to control groups using standard glucometers. Notably, the CGM group also demonstrated greater improvements in dietary adherence and physical activity — suggesting the real-time feedback loop creates accountability that episodic testing simply cannot.

The Protocol: How CGM-Based Prediabetes Reversal Works

Research programs using CGMs for prediabetes reversal typically follow a structured protocol:

• Baseline wear period (2 weeks): Patients wear a CGM without making dietary changes, simply observing how their body responds to their current lifestyle. This establishes a personal glucose baseline and identifies problematic patterns.
• Dietary optimization phase (4–12 weeks): Using CGM data, patients identify foods that cause excessive glucose spikes (generally defined as rising above 140 mg/dL postprandially). A registered dietitian or digital health coach helps restructure meals around the individual's personal response data.
• Exercise integration: CGM data clearly shows patients how even brief walks after meals (10–15 minutes) dramatically flatten glucose spikes — a powerful motivational tool that standard advice cannot replicate.
• Sleep and stress monitoring: CGMs reveal how poor sleep and psychological stress raise fasting glucose, helping patients understand the full lifestyle picture.
• Long-term confirmation: HbA1c retesting at 3 and 6 months confirms whether the intervention has moved patients out of the prediabetes range (below 5.7% from the 5.7–6.4% range).

Current Status (2025)

As of 2025, CGM use for prediabetes is proven as a behavioral tool but not yet universally covered by insurance for this indication. The FDA has cleared several CGMs for use without a prescription — including the Dexcom Stelo and Abbott Lingo, both specifically designed and marketed for metabolic health in people without diabetes. This is a significant development: for the first time, people with prediabetes can access professional-grade CGM technology without a doctor's prescription.

Ongoing trials registered on ClinicalTrials.gov (search terms: "CGM prediabetes," "continuous glucose monitor prevention") continue to refine optimal protocols and identify which patient populations benefit most. Patients interested in participating can search ClinicalTrials.gov directly to find active enrollment studies.

Insurance coverage remains inconsistent. Medicare and most private insurers currently cover CGMs only for patients with diagnosed type 1 or insulin-treated type 2 diabetes. Advocacy organizations are actively pushing for coverage expansion to prediabetes, but formal policy changes are likely 2–4 years away for most payers.

What This Means for Patients

If you have prediabetes, CGM technology is available to you today through over-the-counter options like Dexcom Stelo and Abbott Lingo, typically ranging from $89–$149 per month without insurance. This is a meaningful out-of-pocket cost, but one that many patients and clinicians consider worthwhile given the potential to avoid decades of diabetes management costs.

The evidence is clear: CGMs work best not as standalone devices but as part of a structured program that includes dietary coaching, exercise guidance, and regular follow-up. Simply wearing a sensor without acting on the data produces minimal results. The technology is the tool; behavior change is the intervention.

For patients managing supplies, monitoring their metabolic health, or looking for current CGM technology options, mdsdiabetes.com provides regularly updated resources on available devices and evidence-based protocols.

Speak with your healthcare provider about whether a structured CGM program is appropriate for your situation. Bring your CGM data to appointments — clinicians increasingly know how to interpret it, and it often leads to more personalized, effective care than an HbA1c number alone ever could.